Dr. Alzabin received her BSc and BA in pre-medical studies and urban design and architecture from New York University. She was awarded a scholarship by the NIH to pursue a PhD at New York University School of Medicine. Her doctoral research has been patented and is being developed for immuno-therapeutics in oncology. After, Saba joined Imperial College London, U.K., where she has been awarded a Medical Research Council fellowship for the identification of the basis for patients who are non-responders to tumour necrosis factor alpha antibody therapy. Her findings have supported the investment by companies such as Abbvie and Roche to develop combinatorial immuno-therapy. Dr. Alzabin then joined the University of Oxford to undertake research focused on infectious triggers of autoimmunity, and embarked on an academic-industrial partnership between the Universities of Oxford and Manchester, and Epistem Ltd., where she has established a pre-clinical programme targeting immune-related disorders. She is an avid promoter of academic-industrial collaboration and education, and has been awarded Technology Strategy Board and Knowledge Transfer Partnership grants by the U.K. government to promote her efforts. In addition, Dr. Alzabin holds numerous memberships and advisory board affiliations such as the American Cancer Association, the Royal Society of Medicine, and the Centre for Regenerative Medicine at the University of Manchester. She is now the Co-Founder and Chief Scientific Officer of the first hybrid health platform in the MENA, Nabta Health, which aims to empower women in the region to manage their health.